2024 (14 POSTS)

Allen B, Vincent M, Lipworth L, Panko J, Suh M, Jiang X, Mumma MT, Proctor D. Lung cancer risk and exposure to hexavalent chromium: Results of extended mortality study of workers with low level exposures and quantitative risk assessment using pooled analysis of three cohorts. Poster presentation at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Thompson CM, Heintz MM, Cullen JM, Haws LC. 2024. Letter to the Editor of Environmental Pollution: In regard to Wan et al. (2024), “GenX caused liver injury and potential hepatocellular carcinoma of mice via drinking water even at environmental concentration.” Environ Pollut 355(Aug 15):124171; doi: 10.1016/j.envpol.2024.1241741. PMID: 38776993.

View Abstract

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; doi :10.1016/j.annonc.2023.10.262.

View Abstract

2023 (6 POSTS)

Bylsma LC, Pundole X, Ju C-H, Hooda N, Movva N, Elkhouly E, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol 18(6):821-835; doi: 10.1007/s11523-023-01008-x. PMID: 37930513.

View Abstract

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

View Abstract

Wikoff D, Thompson C, Vincent M, Fitch S, Britt J, Reichert H, Rogers S. 2023. Protocol for the systematic review of formaldehyde and lymphohematopoietic (LHP) cancers. OSF | Protocol_Formaldehyde and LHP SR.pdf.

Pundole X, Ju C-H, Bylsma LC, Hooda N, Movva N, Elkhouly E, Bebb DG, Fryzek J, et al. 2023. Prevalence of delta-like ligand 3 expression in small cell lung cancer. J Clinical Oncology 41:16_suppl e20618.

View Abstract

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037. PMID: 37040387.

View Abstract

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

View Abstract

2022 (8 POSTS)

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

View Abstract

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer.  Adv Ther 39(6):2778–2795; doi:10.1007/s12325-022-02141-1. PMID: 35430673.

View Abstract

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

View Abstract

Bylsma L, Fryzek J, Movva N, Frankenfeld C, Hooda N, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119

View Abstract

Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K,…, Price C, et al. 2022. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis 25(3):444–452; doi: 10.1038/s41391-022-00553-2.

View Abstract

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Supplement 1):5961–5962; doi: 10.1182/blood-2022-167239.

View Abstract

Tice RR, Bassan A, Amberg A, Anger LT, Beal MA, Bellion P, Benigni R, Birmingham J…, Mihalchik-Burhans AL, et al. 2021. In silico approaches in carcinogenicity hazard assessment: Current status and future needs. Comp Toxicol 20(Nov):100191; doi: 10.1016/j.comtox.2021.100191.

View Abstract

Goodman S, Chappell G, Guyton KZ, Pogribny IP, Rusyn I. 2022. Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: An update of a systematic literature review. Mutat Res Rev Mutat Res 789(Jan-Jun):108408; doi: 10.1016/j.mrrev.2021.108408. PMID: 35690411.

View Abstract

2021 (11 POSTS)

Erber L, Goodman S, Wright FA, Chiu WA, Tretyakova NY, Rusyn I. 2021. Intra- and inter-species variability in urinary N7-(1-hydroxy-3-buten-2-yl)guanine adducts following inhalation exposure to 1,3-butadiene. Chem Res Toxicol 34(11):2375-2383; doi: 10.1021/acs.chemrestox.1c00291. PMID: 34726909.

View Abstract

Erber L, Goodman S, Jokipii Krueger CC, Rusyn I, Tretyakova N. 2021. Quantitative nanoLC/NSI+-HRMS method for 1,3-butadiene induced bis-N7-guanine DNA-DNA cross-links in urine. Toxics 9(10):247; doi: 10.3390/toxics9100247. PMID: 34678943.

View Abstract

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer 125(10):1432-1442; doi: 10.1038/s41416-021-01498-4. PMID: 34426664.

View Abstract